1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
Chronic Pain Treatment Market by Product, by Indication, by Application, by Distribution Channel, by End User, by Geography - Global Market Size, Share, Development, Growth, and Demand Forecast, 2014-2024

Chronic Pain Treatment Market by Product, by Indication, by Application, by Distribution Channel, by End User, by Geography - Global Market Size, Share, Development, Growth, and Demand Forecast, 2014-2024

  • December 2018
  • 423 pages
  • ID: 5731299
  • Format: PDF
  • By Prescient & Strategic Intelligence Private Limited

Summary

Table of Contents

Chronic Pain Treatment Market by Product (Drugs, Devices), by Indication (Neuropathic Pain, Arthritis Pain, Chronic Back Pain, Cancer Pain, Migraine, Fibromyalgia), by Application (Musculoskeletal, Neuropathy, Oncology), by Distribution Channel (Direct, Indirect), by End User (Hospitals, Clinics, Nursing Homes, Research Centers & Universities), by Geography (U.S., Canada, Germany, France, U.K., Italy, Spain, Netherlands, Russia, Sweden, Switzerland, Japan, China, India, Australia, South Korea, Brazil, Mexico, Saudi Arabia, South Africa) - Global Market Size, Share, Development, Growth, and Demand Forecast, 2014-2024

Chronic pain treatment market is expected to reach $105.9 billion by 2024, the market growth is primarily driven by the rising prevalence of chronic conditions, surging geriatric population, and increasing government support toward chronic pain management.

Based on product, the chronic pain treatment market is bifurcated into drugs and devices. The category of drugs is further classified into opioids, non-steroidal anti-inflammatory drugs (NSAIDs), anticonvulsants, antidepressants, and other drugs. Opioids dominate the chronic pain drugs market, with an estimated contribution of 36.5% revenue in 2018. Opioids are considered one of the most effective drug classes for the treatment of chronic pain.

On basis of indication, the chronic pain treatment market is categorized into neuropathic pain, arthritis pain, cancer pain, chronic back pain, migraine, fibromyalgia, and others. According to the American Academy of Pain Medicine (AAPM), chronic pain affects approximately 1.5 billion people worldwide, on account of the high prevalence of cardiovascular disorders, cancer, and diabetes. During the forecast period, the market is expected to witness the fastest growth in demand for pain treatment products for cancer pain, followed by migraine.

Chronic pain treatment products are used in several application areas, including musculoskeletal, neuropathy, and oncology. Musculoskeletal indications constitute the largest application area of these products and are estimated to generate revenue of $31.8 billion in the chronic pain treatment market in 2018. This can be mainly attributed to the high prevalence of musculoskeletal disorders, such as osteoarthritis, back pain, and rheumatoid arthritis, across the globe.

On the basis of distribution channel, the chronic pain treatment market is divided into direct and indirect modes, of which the direct mode of distribution led the market in 2017 with 60.1% revenue contribution. The growing emphasis of drug and device manufacturers on direct sales is driving the market growth in this category.

Hospitals; clinics; nursing homes; and research centers and universities are the major end users in the chronic pain treatment market. Hospitals are the largest end users of chronic pain treatment products and are estimated to hold 39.7% market share in 2018. Pain treatment practices are more frequently performed in hospitals, particularly for post-surgical pain. Thus, with the growing number of surgical procedures around the world, hospitals are expected to continue generating a high demand for chronic pain treatment products.

During the forecast period, the chronic pain treatment market is expected to witness the fastest growth in the APAC region. This can be mainly attributed to the high prevalence of chronic pain among people in the region. Among all age groups, the elderly are the most susceptible to chronic conditions, such as arthritis, neuropathic disorders, and back pain. According to the United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP), the number of aged people in the region is expected to increase twofold, from 535 million in 2015 to 1.3 billion by 2050.

To reduce the prevalence of chronic pain in the region, several government organizations are providing advanced healthcare services that help people manage pain-related conditions. For instance, Painaustralia, one of the key Australian pain advocacy bodies working toward improving the quality of life of patients living with pain, launched a national pain strategy in 2011, to provide evidence-based pain management services that focus on interdisciplinary care at all levels of the health system. Through this strategy, several initiatives have been taken to decrease the prevalence of chronic pain in Australia.

Increasing product approvals are paving the way for various market players to expand their product portfolio in the chronic pain treatment industry. For instance, in November 2018, Pfizer Inc. announced that it was granted pediatric exclusivity for LYRICA by the United States Food and Drugs Administration (USFDA). The grant extended the period of the U.S. market exclusivity for LYRICA by an additional six months till June 2019. LYRICA is currently approved in the U.S. for fibromyalgia, diabetic nerve pain, spinal cord injury nerve pain, and pain caused by shingles in adults. It is also approved as an adjunctive therapy for the treatment of partial onset seizures in patients aged four years and above.

Furthermore, in November 2018, Abbott Laboratories launched the dorsal root ganglion (DRG) Invisible Trial System. Abbott’s DRG is a form of neurostimulation therapy that specifically targets the DRG. The therapy blocks pain signals transmitted via the DRG, thereby providing relief in chronic pain. With the DRG Invisible Trial System, the patient can use an Apple iPod touch to manage pain by changing the stimulation settings within prescribed limits.

Some of the other key players operating in the global chronic pain treatment market are Eli Lilly and Company; GlaxoSmithKline plc; Medtronic plc; Boston Scientific Corporation; Novartis AG; Johnson & Johnson; AstraZeneca PLC; Bristol-Myers Squibb Company; Becton, Dickinson and Company; and Sanofi.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Veronica helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A - Pipeline Review, H1 2019

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A - Pipeline Review, H1 2019

  • $ 3500
  • June 2019

Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A - Pipeline Review, H1 2019SummaryDual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein ...

Fibromyalgia - Pipeline Review, H1 2019

Fibromyalgia - Pipeline Review, H1 2019

  • $ 2000
  • March 2019

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline Review, H1 2019SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Fibromyalgia - Pipeline Review, H1 2019, provides ...

Global Neuropathic Pain Market Research Report Forecast to 2023

Global Neuropathic Pain Market Research Report Forecast to 2023

  • $ 4450
  • March 2019

Global Neuropathic Pain Market Research Report, by Type (Peripheral Neuropathy, Entrapment Neuropathy, and Others), by Indication (Diabetic Neuropathy, Spinal Stenosis), by Diagnosis (Imaging, Blood Tests), ...


ref:plp2018

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on